{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:42:16Z","timestamp":1790642536696,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vancomycin is an effective but potentially nephrotoxic antibiotic commonly used for severe infections. Dosing guidelines for vancomycin in obese children and adolescents with or without renal impairment are currently lacking. This study describes the pharmacokinetics of vancomycin in a large pediatric cohort with varying degrees of obesity and renal function to design practical dosing guidelines for this population. A multi-center retrospective population pharmacokinetic study was conducted using data from patients aged 1\u221218 years who received &gt;1 dose of vancomycin and had \u22651 vancomycin concentration measured between January 2006 and December 2012. Besides pharmacokinetic data, age, gender, body weight, creatinine clearance (CL<jats:sub>cr<\/jats:sub>, bedside Schwartz equation), ward, race, and neutropenic status were collected. Population pharmacokinetic analysis and simulations were performed using NONMEM7.4. A total of 1892 patients (5524 samples) were included, with total body weight (TBW) ranging 6\u2212188 kg (1344 normal weight, 247 overweight, and 301 obese patients) and CL<jats:sub>cr<\/jats:sub> down to 8.6 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>. The two-compartment model, with clearance (CL) significantly increasing with TBW and CL<jats:sub>cr<\/jats:sub>, central and peripheral volume of distribution and inter-compartmental clearance increasing with TBW, performed well for all age, weight, and renal function ranges. A dosing guideline is proposed that integrates body weight and CL<jats:sub>cr<\/jats:sub> resulting in effective and safe exposures across all ages, body weight, and renal functions in the pediatric population. We have characterized the full pharmacokinetic profile of vancomycin in obese children and adolescents aged 1\u221218 years and propose a practical dosing guideline that integrates both body weight and renal function.<\/jats:p>","DOI":"10.1208\/s12248-021-00577-x","type":"journal-article","created":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T15:02:42Z","timestamp":1618153362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1\u201318 Years"],"prefix":"10.1208","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-9248","authenticated-orcid":false,"given":"Cornelis","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-6107","authenticated-orcid":false,"given":"Sebastiaan C.","family":"Goulooze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J. M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-3207","authenticated-orcid":false,"given":"Catherine M.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"577_CR1","unstructured":"World Health Organisation 2016. Final report of the Commission on Ending Childhood Obesity. Available at: https:\/\/www.who.int\/end-childhoodobesity\/en\/"},{"key":"577_CR2","doi-asserted-by":"publisher","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults. Lancet. 390(10113):2627\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(17)32129-3.","DOI":"10.1016\/S0140-6736(17)32129-3"},{"key":"577_CR3","doi-asserted-by":"publisher","unstructured":"Barlow SE. Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 120 Suppl:S164\u201392. https:\/\/doi.org\/10.1542\/peds.2007-2329C.","DOI":"10.1542\/peds.2007-2329C"},{"key":"577_CR4","doi-asserted-by":"publisher","unstructured":"Smit C, De Hoogd S, Br\u00fcggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 14(3):275\u201385. https:\/\/doi.org\/10.1080\/17425255.2018.1440287.","DOI":"10.1080\/17425255.2018.1440287"},{"key":"577_CR5","doi-asserted-by":"publisher","unstructured":"Brill MJE, Diepstraten J, Van Rongen A, Van Kralingen S, Van den Anker JN, Knibbe CAJ. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 51(5):277\u2013304. https:\/\/doi.org\/10.2165\/11599410-000000000-00000.","DOI":"10.2165\/11599410-000000000-00000"},{"key":"577_CR6","doi-asserted-by":"publisher","unstructured":"Kendrick JG, Carr RR, Ensom MHH. Pediatric obesity: pharmacokinetics and implications for drug dosing. Clin Ther. 37(9):1897\u2013923. https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.495.","DOI":"10.1016\/j.clinthera.2015.05.495"},{"key":"577_CR7","doi-asserted-by":"publisher","unstructured":"Vaughns JD, Conklin LS, Long Y, Zheng P, Faruque F, Green DJ, et al. Obesity and pediatric drug development. J Clin Pharmacol. 58(5):650\u201361. https:\/\/doi.org\/10.1002\/jcph.1054.","DOI":"10.1002\/jcph.1054"},{"key":"577_CR8","doi-asserted-by":"publisher","unstructured":"Knibbe CAJ, Brill MJE, Van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 55(1):149\u201367. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124354.","DOI":"10.1146\/annurev-pharmtox-010814-124354"},{"key":"577_CR9","doi-asserted-by":"publisher","unstructured":"Krekels EHJ, Knibbe CAJ. Pharmacokinetics and pharmacodynamics of drugs in obese pediatric patients: how to map uncharted clinical territories. Handb Exp Pharmacol. 2019. https:\/\/doi.org\/10.1007\/164_2019_250.","DOI":"10.1007\/164_2019_250"},{"key":"577_CR10","doi-asserted-by":"publisher","unstructured":"Van Rongen A, Van der Aa MP, Matic M, Van Schaik RHN, Deneer VHM, van der Vorst MM. et al., Increased metformin clearance in overweight and obese adolescents: a pharmacokinetic substudy of a randomized controlled trial. Paediatr Drugs. 20(4):365\u201374. https:\/\/doi.org\/10.1007\/s40272-018-0293-1.","DOI":"10.1007\/s40272-018-0293-1"},{"key":"577_CR11","doi-asserted-by":"publisher","unstructured":"Van Rongen A, Vaughns JD, Moorthy GS, Barrett JS, Knibbe CAJ, van den Anker JN. Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. Br J Clin Pharmacol. 80(5):1185\u201396. https:\/\/doi.org\/10.1111\/bcp.12693.","DOI":"10.1111\/bcp.12693"},{"key":"577_CR12","doi-asserted-by":"publisher","unstructured":"Bartelink IH, Van Kesteren C, Boelens JJ, Egberts TCG, Bierings MB, Cuvelier GDE, et al. Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit. 34(5):574\u201383. https:\/\/doi.org\/10.1097\/FTD.0b013e31826051bb.","DOI":"10.1097\/FTD.0b013e31826051bb"},{"key":"577_CR13","doi-asserted-by":"publisher","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatr. Am J Health Syst Pharm. 77(11):835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"577_CR14","doi-asserted-by":"publisher","unstructured":"Lomaestro BM, Lodise TP, Patel N, Drusano GL, Rodvold KA. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 49(4):507\u201314. https:\/\/doi.org\/10.1086\/600884.","DOI":"10.1086\/600884"},{"key":"577_CR15","doi-asserted-by":"publisher","unstructured":"Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP. et al., Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 62(1):1\u20139. https:\/\/doi.org\/10.1128\/AAC.01684-17.","DOI":"10.1128\/AAC.01684-17"},{"key":"577_CR16","doi-asserted-by":"publisher","unstructured":"Khare M, Azim A, Kneese G, Haag M, Weinstein K, Rhee KE, et al. Vancomycin dosing in children with overweight or obesity: a systematic review and meta-analysis. Hosp Pediatr. 10(4):359\u201368. https:\/\/doi.org\/10.1542\/hpeds.2019-0287.","DOI":"10.1542\/hpeds.2019-0287"},{"key":"577_CR17","doi-asserted-by":"publisher","unstructured":"Miller M, Miller JL, Hagemann TM, Harrison D, Chavez-Bueno S, Johnson PN. Vancomycin dosage in overweight and obese children. Am J Heal Pharm. 68(21):2062\u20138. https:\/\/doi.org\/10.2146\/ajhp110107.","DOI":"10.2146\/ajhp110107"},{"key":"577_CR18","doi-asserted-by":"publisher","unstructured":"Heble DE, McPherson C, Nelson MP, Hunstad DA. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy. 33(12):1273\u20137. https:\/\/doi.org\/10.1002\/phar.1321.","DOI":"10.1002\/phar.1321"},{"key":"577_CR19","doi-asserted-by":"publisher","unstructured":"Moffett BS, Kim S, Edwards MS. Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila). 50(5):442\u20136. https:\/\/doi.org\/10.1177\/0009922810393500.","DOI":"10.1177\/0009922810393500"},{"key":"577_CR20","doi-asserted-by":"publisher","unstructured":"Eiland LS, Sonawane KB. Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients. J Pediatr Pharmacol Ther. 19(3):182\u20138. https:\/\/doi.org\/10.5863\/1551-6776-19.3.182.","DOI":"10.5863\/1551-6776-19.3.182"},{"key":"577_CR21","unstructured":"Mahmoud MA, Ebid AHIM, Shouman S, Ebid E. Pharmacokinetics of vancomycin in oncology Egyptian paediatrics: a dosage adjustment trial. Indian J Pharm Sci. 76(1):82\u20136."},{"key":"577_CR22","doi-asserted-by":"publisher","unstructured":"Janssen EJHH, V\u00e4litalo PAJJ, Allegaert K, de Cock RFWW, Simons SHPP, Sherwin CMTT, et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 60(2):1013\u201321. https:\/\/doi.org\/10.1128\/AAC.01968-15.","DOI":"10.1128\/AAC.01968-15"},{"key":"577_CR23","doi-asserted-by":"publisher","unstructured":"Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, et al. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 58(11):6454\u201361. https:\/\/doi.org\/10.1128\/AAC.03620-14.","DOI":"10.1128\/AAC.03620-14"},{"key":"577_CR24","doi-asserted-by":"publisher","unstructured":"Camaione L, Elliott K, Mitchell-Van Steele A, Lomaestro B, Pai MP. Vancomycin dosing in children and young adults: back to the drawing board. Pharmacotherapy. 33(12):1278\u201387. https:\/\/doi.org\/10.1002\/phar.1345.","DOI":"10.1002\/phar.1345"},{"key":"577_CR25","doi-asserted-by":"publisher","unstructured":"Lanke S, Yu T, Rower JE, Balch AH, Korgenski EK, Sherwin CM. AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis. J Clin Pharmacol. 57(1):77\u201384. https:\/\/doi.org\/10.1002\/jcph.782.","DOI":"10.1002\/jcph.782"},{"key":"577_CR26","doi-asserted-by":"publisher","unstructured":"Moffett BS, Ivaturi V, Morris J, Akcan Arikan A, Dutta A. Population pharmacokinetic assessment of vancomycin dosing in the large pediatric patient. Antimicrob Agents Chemother. 63(4). https:\/\/doi.org\/10.1128\/AAC.02359-18.","DOI":"10.1128\/AAC.02359-18"},{"key":"577_CR27","doi-asserted-by":"publisher","unstructured":"Le J, Capparelli EV, Wahid U, Wu YSS, Romanowski GL, Tran TM, et al. Bayesian estimation of vancomycin pharmacokinetics in obese children: matched case-control study. Clin Ther. 37(6):1340\u201351. https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.006.","DOI":"10.1016\/j.clinthera.2015.05.006"},{"key":"577_CR28","unstructured":"Centers for Disease Control and Prevention (CDC). Clinical Growth Charts. https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm. Accessed 2017 Sep 25"},{"key":"577_CR29","unstructured":"World Health Organisation. WHO Child Growth Standards. https:\/\/www.who.int\/childgrowth\/standards\/en\/. Accessed 2017 Sep 25"},{"key":"577_CR30","doi-asserted-by":"publisher","unstructured":"Ceriotti F, Boyd JC, Klein G, Henny J, Queralt\u00f3 J, Kairisto V, et al. Reference intervals for serum creatinine concentrations: assessment of available data for global application. Clin Chem. 54(3):559\u201366. https:\/\/doi.org\/10.1373\/clinchem.2007.099648.","DOI":"10.1373\/clinchem.2007.099648"},{"key":"577_CR31","doi-asserted-by":"publisher","unstructured":"Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 4(11):1832\u201343. https:\/\/doi.org\/10.2215\/CJN.01640309.","DOI":"10.2215\/CJN.01640309"},{"key":"577_CR32","doi-asserted-by":"publisher","unstructured":"Dosne A-G, Bergstrand M, Harling K, Karlsson MO. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn. 43(6):583\u201396. https:\/\/doi.org\/10.1007\/s10928-016-9487-8.","DOI":"10.1007\/s10928-016-9487-8"},{"key":"577_CR33","unstructured":"Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen. Dutch Paediatric Formulary\/Kinderformularium. https:\/\/www.kinderformularium.nl\/. Accessed 2020 Mar 15"},{"key":"577_CR34","unstructured":"Paediatric Formulary Committee. British National Formulary for Children (BNFc) (online). http:\/\/www.medicinescomplete.com. Accessed 2020 Mar 20"},{"key":"577_CR35","doi-asserted-by":"publisher","unstructured":"Smit C, Wasmann RE, Goulooze SC, Wiezer MJ, van Dongen EPA, Mouton JW, et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol. 86(2):303\u201317. https:\/\/doi.org\/10.1111\/bcp.14144.","DOI":"10.1111\/bcp.14144"},{"key":"577_CR36","doi-asserted-by":"crossref","unstructured":"Lewis T V, Harrison DL, Gildon BL, Carter SM, Turman MA. Applicability of the Schwartz equation and the chronic kidney disease in children bedside equation for estimating glomerular filtration rate in overweight children. Pharmacotherapy. 36(6):598\u2013606. doi:10.1002\/phar.1763","DOI":"10.1002\/phar.1763"},{"key":"577_CR37","doi-asserted-by":"publisher","unstructured":"Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 24(1):67\u201376. doi:https:\/\/doi.org\/10.1007\/s00467-008-0997-5","DOI":"10.1007\/s00467-008-0997-5"},{"key":"577_CR38","doi-asserted-by":"publisher","unstructured":"De Cock RFW, Allegaert K, Brussee JM, Sherwin CMT, Mulla H, De Hoog M, et al. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 31(10):2643\u201354. doi:https:\/\/doi.org\/10.1007\/s11095-014-1361-z","DOI":"10.1007\/s11095-014-1361-z"},{"key":"577_CR39","doi-asserted-by":"publisher","unstructured":"Calvier EAM, Krekels EHJ, V\u00e4litalo PAJ, Rostami-Hodjegan A, Tibboel D, Danhof M, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 56(3):273\u201385. doi:https:\/\/doi.org\/10.1007\/s40262-016-0436-x","DOI":"10.1007\/s40262-016-0436-x"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00577-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T17:06:17Z","timestamp":1621530377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00577-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00577-x","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,11]]},"assertion":[{"value":"24 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for this work. C. Smit, S.C. Goulooze, C. M. Sherwin, and C.A.J. Knibbe declare that they have no conflicts of interest. R.J.M. Br\u00fcggemann declares that he has no conflicts of interest with regard to this work. Outside of this work, he has served as a consultant to and has received unrestricted research grants from Astellas Pharma Inc., F2G, Amplyx, Gilead Sciences, Merck Sharpe and Dohme Corp., and Pfizer Inc. All payments were invoiced by the Radboud University Medical Centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"53"}}